Altimmune, Inc. ALT
1.56 USD -0.08 (-5.17%)
Regular-session close
1.61 +0.05 +3.15%
Pre-market · Nov 17, 8:45 AM ET
1.50 Day range 1.67
1.50 52-week range 6.44
- YTD
- -56.79%
- 1 year
- -62.59%
News
benzinga.com Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $14 Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $17 to $14.
benzinga.com B. Riley Securities Reiterates Buy on Altimmune, Lowers Price Target to $11 B. Riley Securities analyst William Woods reiterates Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $13 to $11.
zacks.com ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns Altimmune's Q3 loss is wider than estimates as rising R&D costs weigh on earnings, while pemvidutide advances across MASH, AUD and ALD programs.
seekingalpha.com Altimmune: Still Too Late And Too Capital-Intensive Altimmune remains a 'Sell' as pemvidutide lacks clear differentiation in the competitive MASH landscape and faces significant funding challenges. ALT's share count has doubled year-over-year, with…
seekingalpha.com Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript
marketbeat.com What Altimmune (ALT) Said on Its Q3 Earnings Call Altimmune NASDAQ: ALT is ramping up a late-stage trial of its experimental drug pemvidutide for a serious liver disease and preparing for a December meeting with the U.S. Food and Drug Administration…
benzinga.com Altimmune Q3 2026 Earnings Call Transcript Altimmune (NASDAQ:ALT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Altimmune Q3 EPS $(0.15) Misses $(0.14) Estimate, Sales $0 Miss $1.400K Estimate Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 15.38 percent. This is a 28.57 percent increase over losses of $(0.21)…
globenewswire.com Altimmune Announces Third Quarter 2026 Financial Results and Business Update Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2…benzinga.com Altimmune Publishes IMPACT Phase 2b 48-Week Data In The Lancet Gastroenterology & Hepatology Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profilePublication of…
globenewswire.com Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…benzinga.com Altimmune Reports Phase 2 Results For Pemvidutide In Alcohol Use Disorder, Plans FDA Meeting In December Ahead Of Phase 3 Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD;…
benzinga.com Altimmune To Present Phase 2 RECLAIM Results For Pemvidutide In Alcohol Use Disorder At AASLD Liver Meeting; FDA End-Of-Phase 2 Meeting Set For December First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)Presentation to take…
